60 Degrees Pharmaceuticals, Inc. Warrant (SXTPW NASDAQ) stock market data APIs
$0.0444
0(0%)
as of September 16, 2025
Try our APIs with
free plan!
60 Degrees Pharmaceuticals, Inc. Warrant Financial Data Overview
Price chart is built with
Anychart
60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.
Prev. Close
0.0444
Open
0.0444
High
0.0444
Low
0.0444
52 wk Range
0.0101-0.156
Market Cap
0
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get 60 Degrees Pharmaceuticals, Inc. Warrant data using free add-ons & libraries
Get 60 Degrees Pharmaceuticals, Inc. Warrant Fundamental Data
60 Degrees Pharmaceuticals, Inc. Warrant Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
Get 60 Degrees Pharmaceuticals, Inc. Warrant End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
60 Degrees Pharmaceuticals, Inc. Warrant News
New
60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis
90-day trial measuring change in general fatigue in chronic babesiosis patientsEnrollment expected to commence Q4 2025 and to be completed by Q2 2026Site has clinical expertise in infectious disease t...
60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results
A now resolved supply disruption led to Q2 net product revenue decline but higher profitability due to increased usage of a cash-pay distribution model$1.97 million cash on hand, runway through March ...
60 Degrees Pharma Announces Type C Meeting with FDA to Discuss Development of Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease
Type C meeting will be to discuss a proposed Phase II study of tafenoquine for treatment of babesiosis Transmitted by ticks, babesiosis is a life-threatening parasitic disease increasing in frequency ...
60 Degrees Pharma to Present Review of Safety, Efficacy Data of 8-Aminoquinolines for Malaria and Babesiosis Treatment at ILADS Annual Scientific Meeting in Boston
60 Degrees Pharmaceuticals will present scientific poster on new, long-term safety data on the use of tafenoquine for malaria prevention at the ILADS 2023 annual scientific meeting60 Degrees Pharmaceu...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
